About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiology
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
The University of Kansas Cancer Center
https://www.kucancercenter.org/
2023 Multidisciplinary Oncology Review
2022
Advances in Hematologic Malignancies and Cellular Therapeutics Symposium
2022 Post San Antonio Review
Videos
2021
2021 Virtual KU Hematology and Medical Oncology Review
2021 Post San Antonio Review
2021 KUMC Virtual Multidisciplinary Oncology Review
2020
ASH Review VIRTUAL 2020: Current Updates in Hematologic Diseases
2020 ASCO Highlights
2019
2019 Post San Antonio Breast Cancer Review
ASH 2019 Review: Current Updates in Hematologic Diseases
2019 Lung Cancer and Head & Neck Cancer Symposium
Hematology & Medical Oncology Review 2019
Lung
Hematologic Malignancies
Gastrointestinal
Head and Neck
Genitourinary
Skin
Palliative
General
Event
2018
ASH: Current Updates in Hematologic Diseases
Events
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
M
KU ASCO 2019: Update on CLL Preferred Therapy - BR vs Ibrutinib & Ibrutinib + Rituximab vs. FCR
By
KU Hematology & Medical Oncology Review 2019
FEATURING
Marc Hoffmann
By
KU Hematology & Medical Oncology Review 2019
FEATURING
Marc Hoffmann
0 views
October 4, 2019
Comments
0
Login to view comments.
Click here to Login
Featured Video
01:29
Incyte
Targeting CSF-1R to Manage Inflammation and Fibrosis in GVHD
Featured Video
16:26
Incyte
Effects of a Treatment Option on Hematocrit Control and Spleen Volum…
Feat.
C. Harrison
Hematologic Malignancies
09:31
KU Hematology & Medical Oncology Review 2019
KU ASCO 2019 Hairy Cell Leukemia Highlights - Moxetumomab Pasudotox …
Feat.
A. Yacoub
07:15
KU Hematology & Medical Oncology Review 2019
KU ASCO 2019 CML Updates - Criteria for Treatment Discontinuation &a…
Feat.
A. Yacoub
09:20
KU Hematology & Medical Oncology Review 2019
KU ASCO 2019 MDS & MPN Update - Luspatercept in Lower-Risk MDS &…
Feat.
A. Yacoub
15:41
KU Hematology & Medical Oncology Review 2019
KU ASCO 2019 Targeted Therapy Drugs for AML - CPX-351, FLT3, IDH Inh…
Feat.
T. Lin
12:21
KU Hematology & Medical Oncology Review 2019
KU ASCO 2019 Update on Recent Developments in AML - CX-01, HuF59 Ant…
Feat.
T. Lin
10:39
KU Hematology & Medical Oncology Review 2019
KU ASCO 2019 Myeloma Update: Lenalidomide vs Observation in Patients…
Feat.
A. Abdallah
06:58
KU Hematology & Medical Oncology Review 2019
KU ASCO Review 2019: FDA Approval of Daratumumab in Combination with…
Feat.
A. Abdallah
05:36
KU Hematology & Medical Oncology Review 2019
KU ASCO 2019 Myeloma Update: Efficacy of KRd With or Without Transpl…
Feat.
A. Abdallah
06:42
KU Hematology & Medical Oncology Review 2019
KU ASCO 2019 Myeloma Update: Does Subcutaneous Daratumumab Decrease …
Feat.
A. Abdallah
04:31
KU Hematology & Medical Oncology Review 2019
KU ASCO 2019: Update on CLL Preferred Therapy - BR vs Ibrutinib &…
Feat.
M. Hoffmann
08:34
KU Hematology & Medical Oncology Review 2019
KU ASCO 2019: Update on CLL Preferred Therapy - Venetoclax + Obinutu…
Feat.
M. Hoffmann
12:53
KU Hematology & Medical Oncology Review 2019
KU ASCO 2019 Non Hodgkin Lymphoma Update : Polatuzumab Vedotin for R…
Feat.
M. Hoffmann
